ViroStatics is a privately held small pharmaceutical company dedicated to the discovery and the development of novel compounds for a multifaceted treatment of cancers and viral diseases, focusing on novel, selective, host cell kinase targeted inhibitors.

 

The Team and Advisors combines scientific, business, legal, and technology expertise, spanning the entire process of drug development from translational science through preclinical and clinical drug development.


ViroStatics intends to license its compounds at the preclinical stage, with a patent protection extended beyond 2030.

March 20-22, 2017

ViroStatics will be attending the partnering event at BIO-Europe Spring… Read more

December 12, 2016

Thunder Project selected for Phase I SME instrument by the European Community… Read more

Developing Novel Compounds Targeting Viruses and Cancers

The Company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinase selectivity, efficacy and safety profiles.

Consistent with its well defined mechanism of action, ViroStatics’ lead compound has a good toxicity profile while exerting potent activity in preclinical models against most aggressive cancers with high unmet need such as pancreatic cancer, highly malignant lymphoma and acute leukemia.

LEARN MORE

ViroStatics awarded with H2020 Seal of Excellence

21 June 2016

seal-of-excellence-logoThe project proposal THAMAR related to the development of our CDK inhibitor to target HIV-associated malignancies and to purge viral reservoir submitted under the Horizon 2020’s SME instrument phase 1 call H2020-SME Inst-2016-2017 in the area of Dedicated support to biotechnology SMEs closing the gap from lab to market by ViroStatics following evaluation by an international panel of independent experts WAS SUCCESSFUL IN A HIGHLY COMPETITIVE EVALUATION PROCESS* AS AN INNOVATIVE PROJECT PROPOSAL